The multifaceted role of long non-coding RNA DLEU1 in cancer progression: implications for diagnosis and therapy
DOI:
https://doi.org/10.12775/QS.2024.22.54285Keywords
long non-coding RNA, glioblastoma multiforme, cancerAbstract
INTRODUCTION AND PURPOSE: Long non-coding RNAs are key regulators of gene expression and tumorigenesis. Deleted in leukemia 1 (DLEU1) is significant in cancer development. This article reviews DLEU1's role across cancers, assessing its diagnostic and therapeutic potential.
METHODS: A review of scientific articles from PubMed and Google Scholar was conducted.
DESCRIPTION OF THE STATE OF KNOWLEDGE: DLEU1 drives tumor growth in glioblastoma, esophageal, colorectal, and oral cancers by interacting with key miRNAs and genes, promoting malignancy. In breast and ovarian cancers, DLEU1 modulates migration and invasion via specific pathways. In cervical cancer, DLEU1 is linked to immune modulation and serves as a prognostic marker.
SUMMARY: DLEU1 is a vital regulator in various cancers, offering potential as a diagnostic and therapeutic target.
References
Ponting CP, Oliver PL, Reik W. Evolution and functions of long noncoding RNAs. Cell. 2009;136(4):629-41. https://doi.org/10.1016/j.cell.2009.02.006
Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. Nat Rev Genet. 2009;10(3):155-9. https://doi.org/10.1038/nrg2521
Guttman M, Rinn JL. Modular regulatory principles of large non-coding RNAs. Nature. 2012;482(7385):339-46. https://doi.org/10.1038/nature10887
Rinn JL, Chang HY. Genome regulation by long noncoding RNAs. Annu Rev Biochem. 2012;81:145-66. https://doi.org/10.1146/annurev-biochem-051410-092902
Schmitt AM, Chang HY. Long noncoding RNAs in cancer pathways. Cancer Cell. 2016;29(4):452-63. https://doi.org/10.1016/j.ccell.2016.03.010
Gupta RA, Shah N, Wang KC, et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature. 2010;464(7291):1071-6. https://doi.org/10.1038/nature08975
Tsai MC, Spitale RC, Chang HY. Long intergenic noncoding RNAs: new links in cancer progression. Cancer Res. 2011;71(1):3-7. https://doi.org/10.1158/0008-5472.can-10-2483
Esteller M. Non-coding RNAs in human disease. Nat Rev Genet. 2011;12(12):861-74. https://doi.org/10.1038/nrg3074
Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-96. https://doi.org/10.1056/nejmoa043330
Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. JAMA. 2013;310(17):1842-50. https://doi.org/10.1001/jama.2013.280319
Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008;359(5):492-507. https://doi.org/10.1056/nejmra0708126
Wang KC, Chang HY. Molecular mechanisms of long noncoding RNAs. Mol Cell. 2011;43(6):904-14. https://doi.org/10.1016/j.molcel.2011.08.018
Song C, Zhang J, Zhao Z. DLEU1: A Functional Long Noncoding RNA in Tumorigenesis. Curr Pharm Des. 2020;26(15):1742-1748. https://doi.org/10.2174/1381612826666200122145305
Wang J, Quan X, Peng D. Long non-coding RNA DLEU1 promotes cell proliferation of glioblastoma multiforme. Mol Med Rep. 2019;20:1873-1882. https://doi.org/10.3892/mmr.2019.10428
Cao Y, Yang R, Lee I. Prediction of LncRNA-encoded small peptides in glioma and oligomer channel functional analysis using in silico approaches. PLoS One. 2021;16(3) https://doi.org/10.1371/journal.pone.0248634
Liu X, Chen R, Liu L. SP1-DLEU1-miR-4429 feedback loop promotes cell proliferative and anti-apoptotic abilities in human glioblastoma. Biosci Rep. 2019;39(12) https://doi.org/10.1042/bsr20190994
Lv QL, Wang LC, Li DC. Knockdown lncRNA DLEU1 Inhibits Gliomas Progression and Promotes Temozolomide Chemosensitivity by Regulating Autophagy. Front Pharmacol. 2020;11:560543. https://doi.org/10.3389%2Ffphar.2020.560543
Gutschner T, Diederichs S. The hallmarks of cancer: a long non-coding RNA point of view. RNA Biol. 2012;9(6):703-19. https://doi.org/10.4161/rna.20481
Tian, J., Liu, Z., Yang, Z., et al. LncRNA DLEU1 promotes esophageal squamous cell carcinoma progression by stabilizing DYNLL1 and preventing its ubiquitination. Biochem Biophys Res Commun. 2022;603:139-146. https://doi.org/10.1186%2Fs12967-022-03449-w
Lin P, Li Q, Lv X, Qu J, Wang D, Li A et al. HMGA1 promotes the development of esophageal squamous cell carcinoma by mediating miR-671-5p/lncRNA DLEU1. Panminerva Med. 2023 Jun;65(2):264-266. https://doi.org/10.23736/s0031-0808.19.03843-6
Xu D, Yang F, Fan Y, Jing W, Wen J, Miao W, Ding X, Yang H. LncRNA DLEU1 Contributes to the Growth and Invasion of Colorectal Cancer via Targeting miR-320b/PRPS1. Front Oncol. 2021 May 25;11:640276. https://doi.org/10.3389%2Ffonc.2021.640276
Liu T, Han Z, Li H, Zhu Y, Sun Z, Zhu A. LncRNA DLEU1 contributes to colorectal cancer progression via activation of KPNA3. Mol Cancer. 2018 Aug 11;17(1):118. https://doi.org/10.1186/s12943-018-0873-2
Hatanaka Y, Niinuma T, Kitajima H, Nishiyama K, Maruyama R, Ishiguro K et al. DLEU1 promotes oral squamous cell carcinoma progression by activating interferon-stimulated genes. Sci Rep. 2021 Oct 14;11(1):20438. https://doi.org/10.1038/s41598-021-99736-5
Sun KD, Ni YJ, Qin H, Xu QF. LncRNA DLEU1 facilitates the progression of oral squamous cell carcinoma by miR-126-5p/GAB1 axis. Kaohsiung J Med Sci. 2022 Oct;38(10):950-959. https://doi.org/10.1002/kjm2.12572
Lv T, Liu H, Wu Y, Huang W. Knockdown of lncRNA DLEU1 inhibits the tumorigenesis of oral squamous cell carcinoma via regulation of miR‑149‑5p/CDK6 axis. Mol Med Rep. 2021 Jun;23(6):447. https://doi.org/10.3892/mmr.2021.12086
Nishiyama K, Maruyama R, Niinuma T, Kai M, Kitajima H, Toyota M et al. Screening for long noncoding RNAs associated with oral squamous cell carcinoma reveals the potentially oncogenic actions of DLEU1. Cell Death Dis. 2018 Aug 1;9(8):826. https://doi.org/10.1038/s41419-018-0893-2
Wang C, Xie XX, Li WJ, Jiang DQ. LncRNA DLEU1/microRNA-300/RAB22A axis regulates migration and invasion of breast cancer cells. Eur Rev Med Pharmacol Sci. 2019 Dec;23(23):10410-10421. https://doi.org/10.26355/eurrev_201912_19680
Ma HN, Chen HJ, Liu JQ, Li WT. Long non-coding RNA DLEU1 promotes malignancy of breast cancer by acting as an indispensable coactivator for HIF-1α-induced transcription of CKAP2. Cell Death Dis. 2022 Jul 19;13(7):625. https://doi.org/10.1038/s41419-022-04880-z
Wu Q, Guo L, Jiang F, Li L, Li Z, Chen F. Analysis of the miRNA-mRNA-lncRNA networks in ER+ and ER- breast cancer cell lines. J Cell Mol Med. 2015 Dec;19(12):2874-87. https://doi.org/10.1111/jcmm.12681
Shariatmadar Taleghani A, Zohrab Beigi Y, Zare-Mirakabad F, Masoudi-Nejad A. Exploring ceRNA networks for key biomarkers in breast cancer subtypes and immune regulation. Sci Rep. 2023 Nov 27;13(1):20795. https://doi.org/10.1038/s41598-023-47816-z
Zheng C, Liu S, Qin Z, Zhang X, Song Y. LncRNA DLEU1 is overexpressed in premature ovarian failure and sponges miR-146b-5p to increase granulosa cell apoptosis. J Ovarian Res. 2021 Nov 5;14(1):151. https://doi.org/10.1186%2Fs13048-021-00905-x
Xu H, Wang L, Jiang X. Silencing of lncRNA DLEU1 inhibits tumorigenesis of ovarian cancer via regulating miR-429/TFAP2A axis. Mol Cell Biochem. 2021 Feb;476(2):1051-1061. https://doi.org/10.1007/s11010-020-03971-9
Wang LL, Sun KX, Wu DD, Xiu YL, Chen X, Chen S, Zong ZH, Sang XB, Liu Y, Zhao Y. DLEU1 contributes to ovarian carcinoma tumourigenesis and development by interacting with miR-490-3p and altering CDK1 expression. J Cell Mol Med. 2017 Nov;21(11):3055-3065. https://doi.org/10.1111/jcmm.13217
Chen Q, Hu L, Huang D, Chen K, Qiu X, Qiu B. Six-lncRNA Immune Prognostic Signature for Cervical Cancer. Front Genet. 2020 Oct 14;11:533628. https://doi.org/10.3389/fgene.2020.533628
Lv X, Liu L, Li P, Yuan Y, Peng M, Jin H, Qin D. Constructing a Novel Signature Based on Immune-Related lncRNA to Improve Prognosis Prediction of Cervical Squamous Cell Carcinoma Patients. Reprod Sci. 2022 Mar;29(3):800-815. https://doi.org/10.1007/s43032-022-00851-z
Du X, Pu X, Wang X, Zhang Y, Jiang T, Ge Y, Zhu H. A novel necroptosis-related lncRNA based signature predicts prognosis and response to treatment in cervical cancer. Front Genet. 2022 Dec 6;13:938250. https://doi.org/10.3389%2Ffgene.2022.938250
Gu R, Liu M, Lin P, Feng TY, Yuan H, Ou DQ, Li SQ, Li Q, Zhao G, Zhang J, Li K. [Correlation analysis of Poor Prognosis and Immunotherapy of lncRNAs Related with m 6A Modification in Cervical Cancer]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2022 Jul;53(4):626-636. https://doi.org/10.12182/20220760504
Ding H, Zhang L, Zhang C, Song J, Jiang Y. Screening of Significant Biomarkers Related to Prognosis of Cervical Cancer and Functional Study Based on lncRNA-associated ceRNA Regulatory Network. Comb Chem High Throughput Screen. 2021;24(3):472-482. https://doi.org/10.2174/1386207323999200729113028
Dong A, Xu B, Wang Z, Miao X. Survival‑related DLEU1 is associated with HPV infection status and serves as a biomarker in HPV‑infected cervical cancer. Mol Med Rep. 2022 Mar;25(3):77. https://doi.org/10.3892/mmr.2022.12593
Liu C, Tian X, Zhang J, Jiang L. Long Non-coding RNA DLEU1 Promotes Proliferation and Invasion by Interacting With miR-381 and Enhancing HOXA13 Expression in Cervical Cancer. Front Genet. 2018 Dec 7;9:629. https://doi.org/10.3389/fgene.2018.00629
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Paweł Stanicki, Julita Szarpak, Aldona Pażyra, Natalia Kusak, Natalia Żak, Barbara Jaworska
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 59
Number of citations: 0
